German-based company, Insilico Biotechnology, has announced that it has opened its first subsidiary in the United States, specifically in Boston, MA, which is a biopharmaceutical hub in the country.
German-based company, Insilico Biotechnology, has announced in a Feb. 27, 2020 press release, that it has opened its first subsidiary in the United States, specifically in Boston, MA, which is a biopharmaceutical hub in the country.
The US subsidiary, Insilico Biotechnology Corp., is expected to provide the company with access to growth opportunities, as a result of the size of the market, and will allow the company to strengthen its relationship with its customers based in the US. In addition to developing the US business, the company will provide consulting and services for existing customers.
“Following the opening of the representative office in Singapore, the foundation of the Boston subsidiary is a strategic step to achieve our vision of serving the global biopharmaceutical market as the leading provider of predictive solutions for smart biofactories,” said Klaus Mauch, CEO of Insilico, in the press release.
Brett Lepore, the newly appointed president of Insilico Biotechnology Corp., added, “I am extremely happy about being able to directly contribute to our customers’ successful digital transformation with Insilico as their partner. I am absolutely positive that this is the right time and that Boston is exactly the right place.”
Source: Insilico Biotechnology
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.